Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRY2 | Q49AN0 | 18/20 | 0.57 |
| ▸ | PER2 | O15055 | 16/20 | 0.57 |
| ▸ | CRY1 | Q16526 | 10/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17138574 | 1.00 | CRY2 (0.57) | CRY2PER2CRY1DNM1 | |
| SCHEMBL17138632 | 0.84 | PER2 (0.60) | CRY2PER2CRY1DNM1 | |
| SCHEMBL17138635 | 0.84 | PER2 (0.60) | CRY2PER2CRY1DNM1 | |
| SCHEMBL29558380 | 0.84 | PER2 (0.60) | CRY2PER2CRY1DNM1 | |
| SCHEMBL17138871 | 0.82 | DNM1 (0.57) | CRY2PER2CRY1DNM1 | |
| SCHEMBL30145538 | 0.82 | DNM1 (0.57) | CRY2PER2CRY1DNM1 | |
| SCHEMBL28406050 | 0.82 | CRY2 (0.64) | CRY2PER2CRY1DNM1 | |
| SCHEMBL29448065 | 0.82 | CRY2 (0.64) | CRY2PER2CRY1DNM1 | |
| SCHEMBL30145432 | 0.82 | PER2 (0.50) | CRY2PER2CRY1 | |
| SCHEMBL17138604 | 0.82 | PER2 (0.50) | CRY2PER2CRY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | CRY2 2/4885PER2 188/4885CRY1 1/4885 |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | CRY2 2/4885PER2 188/4885CRY1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.